Quick answers
- What is Maraviroc used for?
- The FDA-approved label (Selzentry, A-S Medication Solutions, November 10, 2023) says: “SELZENTRY is indicated in combination with other antiretroviral agents for the treatment of only CCR5‑tropic human immunodeficiency virus type 1 (HIV‑1) infection in adult and pediatric patients weighing at least 2 kg. Limitations of Use • SELZENTRY is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1 […]. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Maraviroc have a boxed warning?
- Yes. The FDA label for Selzentry has a boxed warning (“WARNING: HEPATOTOXICITY”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Maraviroc?
- The FDA drug shortage list shows “To be discontinued” for a product of this medicine (updated January 20, 2026). Ask your pharmacist about alternatives.
- Has Maraviroc been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Maraviroc?
- 9 companies list prescription products of Maraviroc in the FDA NDC Directory, including A-S Medication Solutions, XLCare Pharmaceuticals, Inc. and Navinta LLC.
What Maraviroc is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
SELZENTRY is indicated in combination with other antiretroviral agents for the treatment of only CCR5‑tropic human immunodeficiency virus type 1 (HIV‑1) infection in adult and pediatric patients weighing at least 2 kg. Limitations of Use • SELZENTRY is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1 […]. …
— FDA label: Selzentry, A-S Medication Solutions, effective November 10, 2023. Read the full label on DailyMed →
The FDA has 10 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Its heading: WARNING: HEPATOTOXICITY
. Read it on the full label →
10 of 10 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated |
|---|---|
| Route | Oral |
| Prescription products | 19 in the FDA NDC Directory |
| Brand names | Selzentry |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| maraviroc 150 mg tablet, film coated | Generic | $8.29 per tablet |
| maraviroc 150 mg tablet, film coated | Brand: Selzentry | $28.02 per tablet |
| maraviroc 300 mg tablet, film coated | Generic | $6.36 per tablet |
| maraviroc 300 mg tablet, film coated | Brand: Selzentry | $28.13 per tablet |
NADAC list of November 4, 2026; these prices took effect between June 17, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- A-S Medication Solutions3 products
- XLCare Pharmaceuticals, Inc.2 products
- Navinta LLC2 products
- Camber Pharmaceuticals, Inc.2 products
- ViiV Healthcare Company2 products
- A2A Integrated Pharmaceuticals2 products
- Zydus Pharmaceuticals USA Inc.2 products
- Rhodes Pharmaceuticals LLC2 products
- i3 Pharmaceuticals, LLC2 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA022128 SELZENTRY | Viiv Hlthcare | August 6, 2007 | 13, latest October 30, 2020 2020: Efficacy · 2018: Labeling · 2016: Efficacy |
Generic approvals (4)
- ANDA203347Hetero Labs Ltd III · February 7, 2022
- ANDA217114Pharmazone · August 17, 2023
- ANDA217880Navinta LLC · May 13, 2025
- ANDA216143Rhodes Pharms · November 4, 2025
Shortage status
To be discontinued · updated January 20, 2026 · first posted January 20, 2026
| Product | Selzentry, Solution, 20 mg/mL Oral Solution Kit | 230 mL Oral Solution per Bottle | 1 Bottle per Carton (NDC 49702-260-55) |
|---|---|
| Company | ViiV Healthcare Company |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Selzentry, A-S Medication Solutions, effective November 10, 2023; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →